The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Using machine learning to predict immunotherapy response in advanced melanoma.
 
Paul Johannet
No Relationships to Disclose
 
Nicolas Coudray
No Relationships to Disclose
 
Douglas M. Donnelly
No Relationships to Disclose
 
George Jour
Stock and Other Ownership Interests - Calithera Biosciences; Celldex; La Jolla Pharma
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb
 
Irineu Illa-Bochaca
No Relationships to Disclose
 
Yuhe Xia
No Relationships to Disclose
 
Douglas Buckner Johnson
Consulting or Advisory Role - Array Biopharma; Bristol-Myers Squibb; Incyte; Merck; Novartis
Research Funding - Bristol-Myers Squibb; Incyte
Patents, Royalties, Other Intellectual Property - Intellectual property and patents pending surrounding use of MHC-II and response to immune therapy
Travel, Accommodations, Expenses - Genentech
 
Lee E Wheless
No Relationships to Disclose
 
James Randall Patrinely
No Relationships to Disclose
 
Anna C. Pavlick
Honoraria - Array BioPharma; Bristol-Myers Squibb; Regeneron; Sanofi; Seagen
Consulting or Advisory Role - Regeneron; Seagen
Research Funding - Bristol-Myers Squibb (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Regeneron (Inst); Replimune (Inst)
Travel, Accommodations, Expenses - Regeneron; Seagen
 
Jeffrey S. Weber
Stock and Other Ownership Interests - Altor BioScience; Biond; CytomX Therapeutics; Protean Biodiagnostics
Honoraria - Altor BioScience; Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Eisai; Genentech; GlaxoSmithKline; Jounce Therapeutics; Kirin Pharmaceuticals; Merck; Moderna Therapeutics; Novartis; Oncorus; Roche; Sellas Life Sciences; Takeda; WindMIL
Consulting or Advisory Role - Altor BioScience; Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Eisai; Genentech; GlaxoSmithKline; Jounce Therapeutics; Kirin Pharmaceuticals; Merck; Moderna Therapeutics; Nektar; Novartis; Oncorus; Protean Biodiagnostics; Roche; Sellas Life Sciences; Takeda Science Foundation; WindMIL
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Merck (Inst); Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - named on a patent for 41BB induced TIL by Moffitt Cancer Center; named on a patent from Biodesix for a PD-1 antibody biomarker; Named on a patent submitted by Moffitt Cancer Center for an IPILIMUMAB biomarker
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; Daiichi Sankyo; Genentech; GlaxoSmithKline; Merck; Novartis; Roche; Takeda
 
Hua Zhong
No Relationships to Disclose
 
Aristotelis Tsirigos
Employment - Intelligencia.AI
Stock and Other Ownership Interests - Intelligencia.AI
Consulting or Advisory Role - Intelligencia.AI
 
Iman Osman
Employment - Dracen (I)
Leadership - Dracen (I)